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A bs tr ac t
Background
The safety and efficacy of hydroxyethyl starch (HES) for fluid resuscitation have not 
been fully evaluated, and adverse effects of HES on survival and renal function have 
been reported.
Methods
We randomly assigned 7000 patients who had been admitted to an intensive care 
unit (ICU) in a 1:1 ratio to receive either 6% HES with a molecular weight of 130 kD 
and a molar substitution ratio of 0.4 (130/0.4, Voluven) in 0.9% sodium chloride or 
0.9% sodium chloride (saline) for all fluid resuscitation until ICU discharge, death, 
or 90 days after randomization. The primary outcome was death within 90 days. 
Secondary outcomes included acute kidney injury and failure and treatment with 
renal-replacement therapy.
Results
A total of 597 of 3315 patients (18.0%) in the HES group and 566 of 3336 (17.0%) 
in the saline group died (relative risk in the HES group, 1.06; 95% confidence interval 
[CI], 0.96 to 1.18; P = 0.26). There was no significant difference in mortality in six 
predefined subgroups. Renal-replacement therapy was used in 235 of 3352 patients 
(7.0%) in the HES group and 196 of 3375 (5.8%) in the saline group (relative risk, 
1.21; 95% CI, 1.00 to 1.45; P = 0.04). In the HES and saline groups, renal injury oc-
curred in 34.6% and 38.0% of patients, respectively (P = 0.005), and renal failure 
occurred in 10.4% and 9.2% of patients, respectively (P = 0.12). HES was associated 
with significantly more adverse events (5.3% vs. 2.8%, P<0.001).
Conclusions
In patients in the ICU, there was no significant difference in 90-day mortality be-
tween patients resuscitated with 6% HES (130/0.4) or saline. However, more patients 
who received resuscitation with HES were treated with renal-replacement therapy. 
(Funded by the National Health and Medical Research Council of Australia and 
others; CHEST ClinicalTrials.gov number, NCT00935168.)
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The administration of intravenous fluids to increase intravascular volume is a frequent intervention in the intensive care 
unit (ICU), but the choice of resuscitation fluid 
remains controversial.1,2 Globally, 0.9% sodium 
chloride (saline) is the most commonly used fluid, 
although colloids are administered as often as 
crystalloids, and hydroxyethyl starch (HES) is the 
most frequently used colloid.3
Several studies have questioned the safety of 
HES in critically ill patients, with particular con-
cern that its use increases the risk of acute kid-
ney injury.4,5 Most concern has focused on the 
use of concentrated HES solutions (10%) with a 
molecular weight of more than 200 kD and a 
molar substitution ratio (the number of hydroxy-
ethyl groups per glucose molecule) of more than 
0.5.4,6 Commonly used HES solutions have a 
lower concentration (6%) with a molecular weight 
of 130 kD and molar substitution ratios of 0.38 
to 0.45. These preparations are available in dif-
ferent crystalloid carrier solutions. The clinical 
effects of lower-molecular-weight HES solutions 
have not been fully evaluated either in large 
clinical trials or in the broad range of ICU pa-
tients to whom they are now commonly admin-
istered.7 Additional concern arose from a recent 
Scandinavian trial reporting that the use of 6% 
HES (130/0.42) significantly increased mortality 
in patients with severe sepsis and septic shock.8
We conducted a large-scale, randomized, con-
trolled trial to evaluate the safety and efficacy of 
6% HES (130/0.4) in 0.9% saline as compared 
with 0.9% saline alone for fluid resuscitation in 
a heterogeneous population of adult patients 
treated in the ICU.
Me thods
Study Oversight
The Crystalloid versus Hydroxyethyl Starch Trial 
(CHEST) was an investigator-initiated, multi-
center, prospective, blinded, parallel-group, ran-
domized, controlled trial conducted in 32 hospi-
tals in Australia and New Zealand.
The study-management committee designed 
the trial. The trial was endorsed by the Austra-
lian and New Zealand Intensive Care Society 
Clinical Trials Group. The study protocol9 (avail-
able with the full text of this article at NEJM.org) 
was approved by the human research ethics 
committee at the Northern Sydney and Central 
Coast Area Health Service, the ethics committee 
at the University of Sydney, and by each participat-
ing institution. Written informed consent before 
randomization or delayed consent was obtained 
from each patient, legal surrogate, or institu-
tional ethics committee.
The statistical analysis plan10 was reported 
previously. Statistical analyses were conducted 
at the George Institute for Global Health. The 
authors vouch for the data and statistical analy-
ses, made the decision to submit the manuscript 
for publication, and assume responsibility for the 
fidelity of the final report to the protocol.
The study was funded by a project grant from 
the National Health and Medical Research Coun-
cil of Australia and by unrestricted grants from 
the New South Wales Ministry of Health and 
Fresenius Kabi, the manufacturer of Voluven. 
Funding agencies had no input into the design, 
conduct, data collection, statistical analysis, or 
writing of the manuscript. Fresenius Kabi sup-
plied the study fluids and distributed them to 
participating sites.
Independent analysis of the concentration 
and degree of molar substitution of HES and the 
concentration of saline was obtained for a ran-
dom sample of 20 bags with the use of gravimet-
ric analysis and nuclear magnetic resonance 
spectroscopy (Chemical Analysis).
Patients
Patients who were 18 years of age or older were 
assessed for eligibility on admission to the ICU. 
Patients who met the eligibility criteria were those 
whom the treating clinician judged to require 
fluid resuscitation, which was defined as the ad-
ministration of a bolus of intravenous fluid over 
and above that required for maintenance or re-
placement fluids. Fluid was administered to cor-
rect hypovolemia at any time during the patient’s 
ICU admission, as determined by the treating cli-
nician and supported by at least one objective 
physiological criterion (Table S1A in the Supple-
mentary Appendix, available at NEJM.org). The 
treating clinicians determined the initial and sub-
sequent volumes and the rate of administration 
of resuscitation fluid, depending on clinical signs 
and the subsequent response to f luid adminis-
tration.
Patients who had received more than 1000 ml 
of HES before screening, those with impending 
or current dialysis-dependent renal failure, and 
those with evidence of intracranial hemorrhage 
on cranial computed tomography were excluded. 
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A full list of exclusion criteria is provided in 
Table S1B in the Supplementary Appendix.
Study Randomization and Treatment
Study treatments were randomly assigned over an 
encrypted Web-based randomization system with 
the use of a minimization algorithm stratified 
according to institution and an admission diag-
nosis of trauma.
Patients were assigned to receive either 6% 
HES (130/0.4) in 0.9% saline (Voluven, Fresenius 
Kabi) or 0.9% saline in indistinguishable Freeflex 
500-ml bags9 for all fluid resuscitation in the 
ICU until discharge, death, or 90 days after ran-
domization.
In accordance with registration by the Thera-
peutic Goods Administration of Australia and 
the New Zealand Medicines and Medical Devices 
Safety Authority for 6% HES (130/0.4), study 
fluid was administered to a maximum dose of 
50 ml per kilogram of body weight per day, fol-
lowed by open-label 0.9% saline for the remain-
der of the 24-hour period.
Study fluid was stopped in patients who were 
treated with any mode of renal-replacement 
therapy. In these patients, treatment with saline 
was recommended, but any other f luid, apart 
from HES, was permitted. The administration of 
resuscitation fluids outside the ICU was not con-
trolled.
All other aspects of patient care, including 
maintenance fluids and nutrition, cardiovascular 
monitoring, pharmacologic support, and respi-
ratory and renal support, were conducted at the 
discretion of the treating clinicians.
Outcome Measures
The primary outcome measure was all-cause 
mortality 90 days after randomization.
Secondary outcomes within the 90-day follow-
up period were the incidence of acute kidney 
injury, as defined with the use of a five-category 
scoring system to evaluate risk, injury, failure, 
loss, and end-stage kidney injury (RIFLE)11; the 
use of renal-replacement therapy; new organ 
failures for cardiovascular, respiratory, coagula-
tion, and liver systems that were not present at 
baseline; duration of mechanical ventilation and 
renal-replacement therapy; and cause-specific 
mortality.
Using the RIFLE diagnostic criteria, we eval-
uated patients for being at risk for kidney dys-
function (RIFLE-R), for injury to the kidney 
(RIFLE-I), and for failure of kidney function 
(RIFLE-F) on the basis of incremental increases 
in serum creatinine levels from baseline and 
decreases in urine output over specified time 
periods. Patients with a complete loss of kidney 
function for more than 4 weeks (RIFLE-L) and 
end-stage kidney disease (RIFLE-E) completed 
the diagnostic criteria (Table S2 in the Supple-
mentary Appendix). Included in the analysis was 
any mode of renal-replacement therapy that was 
prescribed by the attending physician. New organ 
failures for cardiovascular, respiratory, coagula-
tion, and liver systems that were not present at 
baseline were defined by a score of 3 or more on 
the Sequential Organ Failure Assessment (SOFA),12 
which ranges from 0 to 4 for each of six organ 
systems, including neurologic and renal systems, 
with higher scores indicating more severe organ 
dysfunction (Table S3 in the Supplementary Ap-
pendix).
Tertiary outcomes were the duration of ICU 
stay and hospital admission and the rate of death 
in the ICU and hospital.
The primary outcome was also examined in 
six subgroup pairs on the basis of baseline char-
acteristics: the presence or absence of diagnostic 
criteria for urine output for acute kidney injury 
(RIFLE-R and RIFLE-I categories), the presence 
or absence of sepsis at randomization,13 the pres-
ence or absence of trauma with or without trau-
matic brain injury, the score (<25 vs. ≥25) on the 
Acute Physiology and Chronic Health Evaluation 
(APACHE) II14 (ranging from 0 to 71, with higher 
scores indicating an increased risk of death), 
and receipt or nonreceipt of HES before random-
ization.
Data and Study Management
Trained research coordinators collected data at 
each site and entered them into a Web-based 
database. Data monitoring and source data veri-
fication were conducted according to a prespeci-
fied monitoring plan. An independent data and 
safety monitoring committee reviewed data from 
prespecified interim analyses after the enrollment 
of 2000 and 4000 patients.
Statistical Analysis
We determined that a sample size of 7000 patients 
would provide a power of 90% to detect an abso-
lute difference of 3.5 percentage points in 90-day 
mortality on the basis of an estimated baseline 
mortality of 26% at an alpha level of 0.05 with an 
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assumption of a 5% loss to follow-up.10 In addi-
tion, the study had a power of 90% with an alpha 
level of  0.05 to detect an absolute increase in the 
relative risk of acute kidney injury of 1.5 percent-
age points from a baseline incidence of 6%.4
We conducted all analyses on an intention-to-
treat basis. Methods for the handling of missing 
data are outlined in the Supplementary Appen-
dix. We compared binary outcomes using relative 
risks with 95% confidence intervals and chi-
square tests. Continuous outcomes were com-
pared with the use of mean differences and un-
paired t-tests. Adjusted analyses were performed 
with the use of robust Poisson regression for 
binary outcomes and robust linear regression for 
continuous outcomes. Baseline covariates includ-
ed the presence or absence of trauma, age, ICU 
admission source, APACHE II score, and base-
line serum creatinine level. We compared survival 
times using log-rank tests and present these as 
Kaplan–Meier curves. Comparisons of fluid and 
physiological data averaged over the first 4 days 
were performed with the use of t-tests.
For the predefined subgroups, we assessed the 
primary outcome using methods similar to those 
used for the main analysis, and we assessed 
heterogeneity of treatment effects among sub-
group pairs using the test for a common relative 
risk. We conducted post hoc analyses comparing 
changes in serum creatinine levels and urine 
output during the first 7 days in each group and 
in patients who satisfied the diagnostic criteria 
for RIFLE-R, RIFLE-I, and RIFLE-F categories of 
acute kidney injury. All analyses were conducted 




From December 2009 through January 2012, we 
enrolled 7000 patients in 32 adult medical–sur-
gical ICUs in Australia and New Zealand, with 
3500 patients assigned to receive 6% HES 
(130/0.4) in 0.9% saline (HES group) and 3500 to 
receive 0.9% saline (saline group) (Fig. 1). The 
two groups of patients had similar characteris-
tics at baseline (Table 1). The primary outcome 
was available for 3315 patients (94.7%) in the 
HES group and 3336 patients (95.3%) in the sa-
line group.
Fluid Therapy and Treatment Effects
Independent analysis of the random sample of 
study fluids reported the concentration of HES to 
be between 5.97% and 6.00%, with a mean de-
gree of molar substitution of 0.44. The concen-
tration of saline in the HES bags was between 
0.92% and 0.93%.
During the first 4 days, the HES group re-
ceived significantly less study fluid than the sa-
line group (mean [±SD] daily average, 526±425 ml 
vs. 616±488 ml; P<0.001), with most of the vol-
ume administered in the first 24 hours (Fig. S1 
in the Supplementary Appendix).
The HES group also received significantly less 
nonstudy fluid than the saline group (851±675 ml 
vs. 1115±993 ml, P<0.001), resulting in a significant-
ly lower positive net fluid balance (921±1069 ml 
vs. 982±1161 ml, P = 0.03) (Table S4 and Fig. S1 in 
the Supplementary Appendix).
During the first 4 days, the HES group re-
ceived significantly more blood products than the 
saline group (78±250 ml vs. 60±190 ml, P<0.001), 
and central venous pressure was significantly 
higher in the HES group (11.3±4.8 mm Hg vs. 
10.4±4.4 mm Hg, P<0.001) (Fig. S1 and S2 in the 
Supplementary Appendix). There were no sig-
nificant between-group differences in heart rate, 
mean arterial pressure, and lactate levels during 
the first 4 days (Fig. S2 in the Supplementary 
Appendix).
Outcomes
In the HES group, 597 of 3315 patients (18.0%) 
died within 90 days after randomization, as com-
pared with 566 of 3336 patients (17.0%) in the 
saline group (relative risk in the HES group, 1.06; 
95% confidence interval [CI], 0.96 to 1.18; 
P = 0.26) (Table 2). There was no significant dif-
ference in the probability of survival between 
the HES group and the saline group during the 
90 days after randomization (P = 0.27) (Fig. 2A). 
There was no significant heterogeneity in the ef-
fect of treatment on 90-day mortality in any of 
the predefined subgroups (Fig. 2B). Renal-replace-
ment therapy was administered to 235 of 3352 
patients (7.0%) in the HES group and 196 of 
3375 patients (5.8%) in the saline group (relative 
risk, 1.21; 95% CI, 1.00 to 1.45; P = 0.04).
The diagnostic criteria for being at risk for 
various stages of renal injury were as follows: 
renal dysfunction (RIFLE-R), 1788 of 3309 pa-
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7000 Underwent randomization
19,475 Patients were assessed for eligibility
10,612 Were ineligible
111 Were under 18 yr of age
3324 Received fluid previously
512 Received ≥1000 ml of 6% HES (130/0.4)
4 Had known allergic reaction
1193 Had nontraumatic intracranial hemorrhage
1257 Received renal-replacement therapy
256 Had serum creatinine level ≥350 µmol/liter
(4.0 mg/dl)
24 Had severe hypernatremia
9 Had severe hyperchloremia
575 Were pregnant or breast-feeding
1127 Were admitted after cardiac surgery
402 Received treatment for burns or after liver
transplantation
1011 Had limited life expectancy
341 Had limitation of therapy
165 Were previously enrolled in the study
301 Were transferred from another ICU and
received fluid
1863 Were eligible but were excluded
735 Were overlooked for randomization
547 Were withdrawn by clinician
335 Did not provide consent
235 Were excluded for other reasons
11 Had problem accessing the Web
3500 Were assigned to receive
6% hydroxyethyl starch (130/0.4)
3500 Were assigned to receive
0.9% saline
113 (3.2%) Withdrew consent137 (3.9%) Withdrew consent
5 (0.1%) Were lost to follow-up 3 (0.1%) Were lost to follow-up
3323 Provided consent for all data
35 Provided consent for early data only
5 Provided consent for primary 
outcome data only
3340 Provided consent for all data
44 Provided consent for early data only
3 Provided consent for primary 
outcome data only
3384 (96.7%) Were included in the analysis3358 (95.9%) Were included in the analysis
43 (1.2%) Were lost to follow-up
at 90 days
48 (1.4%) Were lost to follow-up
at 90 days
3336 (95.3%) Were included in the 90-day
analysis
3315 (94.7%) Were included in the 90-day
analysis
Figure 1. Assessment, Randomization, and Follow-up of the Patients.
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tients (54.0%) in the HES group and 1912 of 
3335 patients (57.3%) in the saline group (rela-
tive risk, 0.94; 95% CI, 0.90 to 0.98; P = 0.007); 
injury to the kidney (RIFLE-I), 1130 of 3265 pa-
tients (34.6%) in the HES group and 1253 of 
3300 patients (38.0%) in the saline group (relative 






Age — yr 63.1±17.0 62.9±16.9
Male sex — no./total no. (%) 2030/3356 (60.5) 2041/3384 (60.3)
Weight — kg 79.4±21.0 78.6±20.8
Source of admission to ICU — no./total no. (%)
Emergency department 930/3353 (27.7) 931/3379 (27.6)
Hospital floor 659/3353 (19.7) 668/3379 (19.8)
Another ICU 53/3353 (1.6) 41/3379 (1.2)
Another hospital 315/3353 (9.4) 306/3379 (9.1)
Operating room
After emergency surgery 625/3353 (18.6) 630/3379 (18.6)
After elective surgery 771/3353 (23.0) 803/3379 (23.8)
Diagnosis on admission — no./total no. (%)
Surgical cases 1426/3353 (42.5) 1450/3379 (42.9)
Nonsurgical cases 1920/3353 (57.3) 1926/3379 (57.0)
APACHE II score — median (interquartile range)† 17.0 (12.0–22.0) 17.0 (12.0–23.0)
Time from ICU admission to randomization — hr 10.9±156.5 11.4±165.4
Physiological variables
Heart rate — beats/min 89.3±23.6 88.8±23.3
Mean arterial pressure — mm Hg 74.0±14.9 73.7±14.6
Central venous pressure — mm Hg 9.5±5.4 8.9±5.1
Lactate — mmol/liter 2.1±2.0 2.0±1.5
Mechanical ventilation — no./total no. (%) 2131/3326 (64.1) 2177/3354 (64.9)
Use of vasopressor — no./total no. (%) 1520/3337 (45.5) 1551/3361 (46.1)
Serum creatinine — µmol/liter 101.5±57.1 100.1±58.0
Urine output 6 hr before randomization  — ml 453.5±418.3 426.6±422.9
Predefined subgroups — no./total no. (%)
RIFLE criteria for acute kidney injury‡ 522/1449 (36.0) 511/1421 (36.0)
Sepsis 979/3355 (29.2) 958/3376 (28.4)
Trauma 267/3358 (8.0) 265/3384 (7.8)
Traumatic brain injury 28/3338 (0.8) 30/3365 (0.9)
APACHE II score ≥25 597/3335 (17.9) 624/3356 (18.6)
Receipt of HES before randomization 509/3347 (15.2) 508/3372 (15.1)
* Plus–minus values are means ±SD. There were no significant differences between the groups except for central venous 
pressure (P<0.001) and lactate level (P<0.05). To convert the values for creatinine to milligrams per deciliter, divide by 
88.4. HES denotes hydroxyethyl starch, and ICU intensive care unit.
† Scores on the Acute Physiology and Chronic Health Evaluation (APACHE) II range from 0 to 71, with higher scores in-
dicating an increased risk of death.
‡ RIFLE (risk, injury, or failure) criteria for acute kidney injury at baseline were calculated from measures of available 
urine output only in patients who satisfied the criteria for risk and injury.  Changes in serum creatinine levels were not 
applicable.
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risk, 0.91; 95% CI, 0.85 to 0.97; P = 0.005); and 
failure of kidney function (RIFLE-F), 336 of 3243 
patients (10.4%) in the HES group and 301 of 
3263 patients (9.2%) in the saline group (relative 
risk, 1.12; 95% CI, 0.97 to 1.30; P = 0.12).
Post hoc analysis showed that serum creati-
nine levels were significantly increased and urine 
output was significantly decreased in the HES 
group, as compared with the saline group, during 
the first 7 days (P = 0.004 and 0.003, respectively) 
(Fig. 3). In addition, when the creatinine and 
urine-output components of each RIFLE catego-
Table 2. Outcomes and Adverse Events.*
Variable HES Saline
Relative Risk 
(95% CI) P Value
Outcome
Primary outcome of death at day 90 —  
no./total no. (%)
597/3315 (18.0) 566/3336 (17.0) 1.06 (0.96 to 1.18) 0.26
Secondary outcomes — no./total no. (%)
Renal outcomes
RIFLE-R 1788/3309 (54.0) 1912/3335 (57.3) 0.94 (0.90 to 0.98) 0.007
RIFLE-I 1130/3265 (34.6) 1253/3300 (38.0) 0.91 (0.85 to 0.97) 0.005
RIFLE-F 336/3243 (10.4) 301/3263 (9.2) 1.12 (0.97 to 1.30) 0.12
Use of renal-replacement therapy 235/3352 (7.0) 196/3375 (5.8) 1.21 (1.00 to 1.45) 0.04
New organ failure†
Respiratory 540/2062 (26.2) 524/2094 (25.0) 1.05 (0.94 to 1.16) 0.39
Cardiovascular 663/1815 (36.5) 722/1808 (39.9) 0.91 (0.84 to 0.99) 0.03
Coagulation 142/2987 (4.8) 119/3010 (4.0) 1.20 (0.95 to 1.53) 0.13
Hepatic 55/2830 (1.9) 36/2887 (1.2) 1.56 (1.03 to 2.36) 0.03
Tertiary outcomes — no./total no. (%)
Death in ICU 364/3313 (11.0) 360/3331 (10.8) 1.02 (0.89 to 1.17) 0.81
Death within 28 days 458/3313 (13.8) 437/3331 (13.1) 1.05 (0.93 to 1.19) 0.40
Death in hospital 483/3307 (14.6) 456/3324 (13.7) 1.06 (0.95 to 1.20) 0.30
Mean Difference (95% CI)
Service utilization — no.
Days in ICU 7.3±0.2 6.9±0.2 0.4 (0.0 to 0.9) 0.07
Days in hospital 19.3±0.3 19.1±0.3 0.2 (-0.8 to 1.1) 0.72
Days receiving mechanical ventilation 6.0±0.2 5.7±0.2 0.4 (-0.1 to 0.8) 0.12
Days receiving renal-replacement therapy 5.6±0.4 5.5±0.4 0.1 (-0.1 to 1.2) 0.86
Treatment-related adverse events‡
Any event — no./total no. (%) 180/3416 (5.3) 95/3358 (2.8) <0.001
Pruritus 137/3416 (4.0) 73/3358 (2.2)
Skin rash 34/3416 (1.0) 16/3358 (0.5)
Other 9/3416 (0.3) 6/3358 (0.2)
Serious adverse events — no./total no. (%)§ 2/3416 (0.1) 2/3358 (0.1) 0.98
* Plus–minus values are means ±SE.
† New organ failure was defined as a Sequential Organ Failure Assessment (SOFA) score12 of at least 3 for each category in patients who did 
not have such organ failure at baseline.
‡ Adverse events in the HES group include those in patients who received HES both before and after randomization.
§ Among the serious (nonfatal) treatment-related adverse events were one case each of anaphylactic shock and extravasation of fluid causing 
airway obstruction in the HES group and one case each of toxic epidermal necrolysis requiring unblinding of the study-group assignment 
and unexplained severe hypotension in the saline group.
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Figure 2. Probability of Survival and the Risk of Death at 90 Days, According to Subgroup.
Panel A shows Kaplan–Meier estimates of the probability of survival for patients receiving either HES (6% hydroxy-
ethyl starch [130/0.4]) or saline. The P value was calculated by means of the log-rank test. Panel B shows the relative 
risk of death at 90 days for the six predefined subgroups. The size of the square representing the risk ratio reflects 
the relative numbers in each group. The horizontal bars represent 95% confidence intervals. P values are for hetero-
geneity for each subgroup.
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ry were analyzed separately, the relative risks of 
meeting the criteria for the risk of kidney dys-
function (RIFLE-R) or kidney injury (RIFLE-I) 
were higher in the HES group than in the saline 
group (Fig. S3 in the Supplementary Appendix).
There was no significant between-group dif-
ference in rates of death in the ICU, at 28 days, 
and in the hospital or in rates of new respiratory 
or new coagulation organ failure. The incidence 
of new cardiovascular organ failure was signifi-
cantly lower in the HES group than in the saline 
group (36.5% vs. 39.9%) (relative risk, 0.91; 95% 
CI, 0.84 to 0.99; P = 0.03). The incidence of new 
hepatic organ failure was significantly higher in 
the HES group than in the saline group (1.9% 
vs. 1.2%) (relative risk, 1.56; 95% CI, 1.03 to 
2.36; P = 0.03). There were no significant differ-
ences in the duration of mechanical ventilation, 
of renal-replacement therapy, or of ICU or hospi-
tal stays between the two groups (Table 2). 
There was no significant between-group differ-
ence in cause-specific mortality within the 90-
day follow-up period (Table S5 in the Supple-
mentary Appendix). The main results were similar 
after adjustment for baseline covariates (Table 
S6 in the Supplementary Appendix).
The use of HES was associated with a sig-
nificant increase in the rate of adverse events 
(5.3 vs. 2.8%, P<0.001). Of these events, pruritus 
and rash were the most common (Table 2).
Discussion
In this randomized, controlled trial, there was no 
significant difference in mortality at 90 days in a 
heterogeneous population of ICU patients who 
received 6% HES (130/0.4) in 0.9% saline and 
those who received 0.9% saline alone for fluid re-
suscitation. The effect on mortality did not differ 
significantly in six predefined subgroup pairs.
Our study was a large-scale, pragmatic trial 
modeled on the Saline versus Albumin Fluid Evalu-
ation (SAFE) trial.15 We sought to minimize the 
risk of bias through centralized randomization, 
allocation concealment, and blinding of study-
group assignments. We used a robust primary 
outcome measured at an interval relevant to this 
study population.16,17 To further minimize the risk 
























































































Figure 3. Serum Creatinine Levels and Urine Output through Day 6.
Day 0 was defined as the day of randomization to the end of that day, which 
averaged 12 hours in the two study groups. P values are for the between-
group comparisons of means of the individual daily averages for 7 days, in-
cluding day 0. To convert the values for creatinine to milligrams per deci-
liter, divide by 88.4.
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including predefined subgroups, before the un-
blinding of study-group assignments.10
A limitation of our study is that the observed 
rate of death was lower than predicted. This was 
due, in part, to the exclusion of patients with 
intracranial hemorrhage and those whom clini-
cians considered unlikely to survive, as well as 
the inclusion of patients who had undergone 
elective surgery. In addition, patients were re-
cruited after admission to the ICU, when the 
requirements for fluid resuscitation are often 
less than those for patients in the emergency 
department or the operating room.
Despite these limitations, our trial had suf-
ficient statistical power to detect an absolute 
mortality difference of 3 percentage points. Our 
results are consistent with a treatment effect 
that lies between a relative decrease of 4% or a 
relative increase of 18% in mortality arising 
from resuscitation with HES.
A fundamental reason for conducting our 
study was to determine whether currently used 
HES solutions increased the risk of acute kidney 
injury in ICU patients. Resuscitation with HES 
resulted in a 21% relative increase in the number 
of patients treated with renal-replacement ther-
apy. Although criteria for the initiation of renal-
replacement therapy were not outlined in the 
protocol and such therapy was initiated at the 
discretion of the attending clinicians, the clini-
cians were unaware of study-group assignments, 
which made it unlikely that the difference was 
caused by variations in thresholds for initiating 
therapy.18
The RIFLE score is a composite-end-point 
measure that combines effects on serum creati-
nine levels and urine output. In our study, the 
use of HES had opposite effects on the two com-
ponents of this score, as compared with saline. 
Our post hoc analysis showed that treatment 
with HES was associated with increased urine 
output in patients with less severe acute kidney 
injury, which may have been due to increased 
intravascular volume or through a diuretic ef-
fect.19 Conversely, serum creatinine levels were 
consistently higher in the HES group, suggest-
ing a progressive reduction in creatinine clear-
ance and more severe acute kidney injury.
The use of HES was associated with the ad-
ministration of lower volumes of resuscitation 
fluid, although the ratio between HES and saline 
was similar to that observed in other blinded 
trials, suggesting that the use of HES was not 
associated with a substantive volume-sparing ef-
fect.8,20,21
The use of HES was also associated with in-
creased use of blood products and a decrease in 
the rate of new cardiovascular failure; the latter, 
as defined by the SOFA score, indicates a reduc-
tion in the use of vasopressors, which was most 
likely due to increased intravascular expansion. 
However, this rate reduction was not associated 
with differences in other resuscitation end points, 
such as mean arterial pressure or serum lactate 
levels. Conversely, the use of HES was associated 
with new hepatic failure, which as defined by 
the SOFA score indicates an increase in serum 
bilirubin levels.
The use of HES was associated with an in-
creased incidence of adverse events, particularly 
pruritus and rash. Our observations are consis-
tent with studies that have shown increased tis-
sue accumulation of HES within the reticuloendo-
thelial system, which is manifested cutaneously 
as pruritus22 and may lead to acute kidney and 
hepatic injury.23,24
In studies involving patients with severe sep-
sis, HES was associated with increased mortality 
and acute kidney injury, resulting in the need for 
renal-replacement therapy.4,8 The patients in our 
study were at lower risk for death than the pa-
tients in these studies, but the point estimate for 
an increased relative risk of death and acute 
kidney injury associated with HES was consis-
tent with the effects seen in these trials.
In conclusion, our study does not provide evi-
dence that resuscitation with 6% HES (130/0.4), 
as compared with saline, in the ICU provides any 
clinical benefit to the patient. Indeed, the use 
of HES resulted in an increased rate of renal-
replacement therapy. Thus, the selection of re-
suscitation fluid in critically ill patients requires 
careful consideration of its safety, its potential 
effect on patient-centered outcomes, and its cost.
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